CS
NKTR icon

Candriam SCA’s Nektar Therapeutics NKTR Stock Holding History

Candriam SCA’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,306
Closed -$103K – 699
2024
Q3 		$103K Hold
5,306
– – ﹤0.01% 681
2024
Q2 		$98.7K Buy
+5,306
New +$112K ﹤0.01% 686
2023
Q1 		– Sell
-39,729
Closed -$1.35M – 911
2022
Q4 		$1.35M Sell
39,729
-6,000
-13% -$290K 0.01% 652
2022
Q3 		$2.19M Hold
45,729
– – 0.02% 564
2022
Q2 		$2.61M Hold
45,729
– – 0.02% 446
2022
Q1 		$3.7M Buy
+45,729
New +$6.77M 0.03% 408
2021
Q2 		– Sell
-20,406
Closed -$5M – 927
2021
Q1 		$5M Hold
20,406
– – 0.04% 375
2020
Q4 		$5.2M Sell
20,406
-656
-3% -$170K 0.04% 384
2020
Q3 		$5.24M Hold
21,062
– – 0.05% 350
2020
Q2 		$7.32M Sell
21,062
-4,671
-18% -$1.46M 0.08% 266
2020
Q1 		$8.14M Hold
25,733
– – 0.09% 252
2019
Q4 		$8.33M Sell
25,733
-267
-1% -$77.4K 0.09% 256
2019
Q3 		$7.1M Sell
26,000
-1,283
-5% -$471K 0.09% 248
2019
Q2 		$14.5M Sell
27,283
-1,303
-5% -$653K 0.18% 132
2019
Q1 		$14.4M Sell
28,586
-1,161
-4% -$688K 0.18% 123
2018
Q4 		$14.7M Buy
29,747
+500
+2% +$302K 0.23% 102
2018
Q3 		$26.7M Buy
29,247
+20,128
+221% +$17.2M 0.36% 57
2018
Q2 		$6.68M Buy
+9,119
New +$10.5M 0.11% 244
2018
Q1 		– Sell
-10,733
Closed -$9.62M – 778
2017
Q4 		$9.62M Sell
10,733
-6,594
-38% -$3.9M 0.17% 157
2017
Q3 		$6.24M Buy
17,327
+1,927
+13% +$603K 0.11% 230
2017
Q2 		$4.52M Buy
15,400
+9,067
+143% +$2.62M 0.08% 279
2017
Q1 		$2.23M Sell
6,333
-5,334
-46% -$1.2M 0.04% 423
2016
Q4 		$2.15M Sell
11,667
-1,666
-12% -$339K 0.05% 357
2016
Q3 		$3.44M Sell
13,333
-6,867
-34% -$1.77M 0.08% 257
2016
Q2 		$4.31M Sell
20,200
-7,133
-26% -$1.59M 0.11% 206
2016
Q1 		$5.61M Sell
27,333
-6,014
-18% -$1.16M 0.14% 175
2015
Q4 		$8.43M Sell
33,347
-7,533
-18% -$1.55M 0.23% 117
2015
Q3 		$6.72M Buy
40,880
+11,547
+39% +$2.04M 0.17% 160
2015
Q2 		$5.5M Buy
29,333
+8,000
+38% +$1.38M 0.11% 223
2015
Q1 		$3.52M Buy
21,333
+1,000
+5% +$206K 0.07% 309
2014
Q4 		$4.73M Buy
+20,333
New +$4.35M 0.1% 240

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Candriam SCA's NKTR Position: Q4 2024 in Review

Candriam SCA sold out of Nektar Therapeutics (NKTR) in Q4 2024, closing a stake of 5,306 shares — an estimated $103K sold.

Candriam SCA first reported a position in NKTR in Q4 2014 and held it in 31 quarters. The position peaked at $26.7M in Q3 2018. 143 funds tracked by Wall St. Rank hold NKTR as of Q4 2024.

  • Candriam SCA reported no remaining Nektar Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Candriam SCA sold 5,306 Nektar Therapeutics shares in Q4 2024, an estimated $103K.
  • Candriam SCA first reported a position in Nektar Therapeutics in Q4 2014 and held it in 31 quarters.
  • Candriam SCA's Nektar Therapeutics position peaked at $26.7M in Q3 2018.
  • 143 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2024.

Based on Candriam SCA's 13F filing for Q4 2024, filed 7 Feb 2025.